New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 21, 2012
12:16 EDTAMRN, BASFYBASF acquisition a positive for Amarin, says Leerink
Leerink views BASF's (BASFY) acquisition of Pronova BioPharma a positive for Amarin (AMRN). The firm believes the deal sets a high floor value for Amarin's Vascepa and reiterates an Outperform rating on the stock with a $27 fair value estimate.
News For AMRN;BASFY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2015
09:11 EDTAMRNEuropean Society of Cardiology
Subscribe for More Information
August 25, 2015
07:08 EDTBASFYBASF added to Best of Bernstein list at Bernstein
Bernstein believes that the decline of BASF's stock has created a buying opportunity, as the firm thinks that the company's fundamentals remain strong. Bernstein predicts that the company will generate 6% EBIT growth this year, beating the consensus outlook and its guidance. It keeps an Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use